Insulet Corporation $PODD Shares Acquired by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC boosted its position in Insulet Corporation (NASDAQ:PODD) by 2.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,017 shares of the medical instruments supplier’s stock after buying an additional 45 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Insulet were worth $634,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in PODD. Larson Financial Group LLC lifted its holdings in Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 81 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in Insulet in the 1st quarter worth $26,000. SouthState Corp lifted its holdings in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares in the last quarter. Kozak & Associates Inc. acquired a new position in Insulet in the 2nd quarter worth $32,000. Finally, Trust Co. of Toledo NA OH acquired a new position in Insulet in the 2nd quarter worth $35,000.

Insider Transactions at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $318.59 on Monday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a fifty-two week low of $226.50 and a fifty-two week high of $353.50. The firm has a 50-day simple moving average of $326.22 and a 200 day simple moving average of $302.53. The company has a market cap of $22.43 billion, a PE ratio of 96.84, a P/E/G ratio of 2.66 and a beta of 1.40.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the prior year, the firm earned $0.55 EPS. The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on PODD. Rothschild & Co Redburn boosted their price objective on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. JPMorgan Chase & Co. upped their target price on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Citigroup restated a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. Canaccord Genuity Group upped their target price on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Finally, Piper Sandler upped their target price on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $348.05.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.